What type of study is this?

This is a Systematic Review study.

Comparison of safety profile of DPP4 inhibitors with SGLT2 inhibitors in type 2 diabetes mellitus: systematic review

View Full Paper

Ask AI

Bookmark

Authors

Systematic review compares safety outcomes of DPP-4 and SGLT2 inhibitors in type 2 diabetes, highlighting adverse events.

DPP-4 inhibitors showed a higher overall incidence of adverse events compared to SGLT2 inhibitors, with rates at 66% versus 34%.
The study analyzed data from 20 trials, including 8 studies on SGLT2 inhibitors with 946 participants and 12 on DPP-4 inhibitors with 1903 participants.
This systematic review assessed randomized controlled trials and observational studies comparing the safety outcomes of both inhibitor classes when added to metformin.
Individualized therapy based on patient characteristics is crucial, given the variation in adverse events between the two drug classes.

Nimavat et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark